Cadmium, active smoking and renal function deterioration in patients with type 2 diabetes

被引:11
|
作者
Oosterwijk, Milou M. [1 ]
Hagedoorn, Ilse J. M. [1 ]
Maatman, Ronald G. H. J. [2 ]
Bakker, Stephan J. L. [3 ]
Navis, Gerjan [3 ]
Laverman, Gozewijn D. [1 ,4 ]
机构
[1] Ziekenhuis Grp Twente, Dept Internal Med Nephrol, Zilvermeeuw 1, Almelo, Netherlands
[2] Medlon BV, Dept Clin Chem, Enschede, Netherlands
[3] Univ Groningen, Univ Med Ctr Groningen, Dept Internal Med, Div Nephrol, Hanzepl 1, Groningen, Netherlands
[4] Univ Twente, Biomed Signals & Syst, Enschede, Netherlands
关键词
cadmium; kidney disease; lifestyle; smoking; type; 2; diabetes; BLOOD-PRESSURE CONTROL; CHRONIC KIDNEY-DISEASE; EXPOSURE; LEAD; NEPHROPATHY; TOXICITY; PROGRESSION; POPULATION;
D O I
10.1093/ndt/gfac270
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background Cadmium is an established nephrotoxin, present in cigarette smoke. We investigated the hazards of cadmium concentration and smoking status on renal function deterioration. We furthermore discerned whether the association of cadmium concentration with renal function deterioration is attributable to smoking status. Methods Prospective analyses were performed in data of 226 patients of the DIAbetes and LifEstyle Cohort Twente-1 (DIALECT). Cadmium concentrations were determined from EDTA whole-blood. Smoking status was determined via a self-administered questionnaire. Renal function deterioration was defined as need for renal replacement therapy or a persistent decline of >= 30% in estimated glomerular filtration rate from baseline for at least 3 months. Multivariable Cox regression models were performed to calculate hazard ratios (HRs) for the association between smoking status, cadmium concentration and renal function deterioration. Results Median (interquartile range) whole-blood cadmium was 2.9 (1.9-5.1) nmol/L. Active smokers had significantly higher cadmium [7.4 (3.3-11.7) nmol/L] compared with never smokers [2.6 (1.6-4.2) nmol/L] and former smokers [2.8 (1.8-4.8) nmol/L]. During median follow-up for 6 (4-8) years, renal function deterioration occurred in 60 persons (27%). Both cadmium and active smoking were associated with an increased hazard for renal function deterioration [HR 1.37, 95% confidence interval (95% CI) 1.06-1.78 and 3.77, 95% CI 1.72-8.29, respectively]. In a multivariable model with both smoking status and cadmium concentration included, active smokers have an increased risk for renal function deterioration (HR 3.00, 95% CI 1.22-7.40), while the association between cadmium and renal function deterioration lost statistical significance (HR 1.16, 95% CI 0.87-1.54). Conclusions Active smoking is associated with progressive kidney disease in type 2 diabetes. The association between cadmium concentration and renal function deterioration in large part determined by smoking status. Extensive assessment of smoking status may be useful in patients with type 2 diabetesat high risk of kidney damage.
引用
收藏
页码:876 / 883
页数:8
相关论文
共 50 条
  • [41] Effect of metabolic syndrome and of its individual components on renal function of patients with type 2 diabetes mellitus
    Moehlecke, M.
    Leitao, C. B.
    Kramer, C. K.
    Rodrigues, T. C.
    Nickel, C.
    Silveiro, S. P.
    Gross, J. L.
    Canani, L. H.
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2010, 43 (07) : 687 - 693
  • [42] Association of kidney disease measures with risk of renal function worsening in patients with hypertension and type 2 diabetes
    Viazzi, Francesca
    Piscitelli, Pamela
    Giorda, Carlo
    Ceriello, Antonio
    Genovese, Stefano
    Russo, Giuseppina T.
    Fioretto, Paola
    Guida, Pietro
    De Cosmo, Salvatore
    Pontremoli, Roberto
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2017, 31 (02) : 419 - 426
  • [43] Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study
    Davis, T. M. E.
    Ting, R.
    Best, J. D.
    Donoghoe, M. W.
    Drury, P. L.
    Sullivan, D. R.
    Jenkins, A. J.
    O'Connell, R. L.
    Whiting, M. J.
    Glasziou, P. P.
    Simes, R. J.
    Kesaniemi, Y. A.
    Gebski, V. J.
    Scott, R. S.
    Keech, A. C.
    DIABETOLOGIA, 2011, 54 (02) : 280 - 290
  • [44] Biomarkers of renal dysfunction among Ghanaian patients with type 2 diabetes mellitus- a cross-sectional study
    Amoah, Brodrick Yeboah
    Asare, George Awuku
    Yeboah, Francis Agyemang
    Obirikorang, Christian
    Asiedu, Bernice
    Mohammed, Arab Omaima
    INTERNATIONAL JOURNAL OF DIABETES IN DEVELOPING COUNTRIES, 2018, 38 (04) : 437 - 444
  • [45] Sarcopenia associated with renal function in the patients with type 2 diabetes
    Yang, Rongrong
    Zhang, Yongze
    Shen, Ximei
    Yan, Sunjie
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 118 : 121 - 129
  • [46] The effect of dapagliflozin on renal function in patients with type 2 diabetes
    Kohan, Donald Elliott
    Fioretto, Paola
    Johnsson, Kristina
    Parikh, Shamik
    Ptaszynska, Agata
    Ying, Lisa
    JOURNAL OF NEPHROLOGY, 2016, 29 (03) : 391 - 400
  • [47] Cadmium Is Associated with Type 2 Diabetes in a Superfund Site Lead Smelter Community in Dallas, Texas
    Little, Bert B.
    Reilly, Robert
    Walsh, Brad
    Vu, Giang T.
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2020, 17 (12) : 1 - 13
  • [48] Exposure to lead and cadmium is associated with fasting plasma glucose and type 2 diabetes in Chinese adults
    Wang, Bin
    Chen, Chi
    Zhang, Wen
    Chen, Yi
    Xia, Fangzhen
    Wang, Ningjian
    Lu, Yingli
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2022, 38 (08)
  • [49] Systolic blood pressure as a predictor of incident albuminuria and rapid renal function decline in type 2 diabetic patients
    Sheen, Yi-Jing
    Lin, Jiann-Liang
    Li, Tsai-Chung
    Bau, Cho-Tsan
    Sheu, Wayne H. -H.
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2014, 28 (06) : 779 - 784
  • [50] Altered renal function in normoalbuminuric type 2 diabetes
    Futrakul, N
    Vongthavarawat, V
    Chairatanarat, T
    Sirisalipotch, S
    Futrakul, P
    Suwanwalaikorn, S
    RENAL FAILURE, 2004, 26 (06) : 727 - 728